The UK is edging closer to finalizing its regulatory sovereignty from the EU, but success will depend on its ability to keep pace with rapid medtech developments, such as those driven by artificial intelligence (AI).
The Association of British HealthTech Industries (ABHI) warns in a recent report that the “process of initial and ongoing approval, and of post-market surveillance, needs to reflect the rapid pace of iteration in AI-supported technology,”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?